October 27, 2014 4:13 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons (ACS) Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care (SOC). The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco. “Owed largely to their potency, opioids have been the cornerstone of postsurgical pain management despite inherent risks and side effects which can delay the recovery process and pose substantial patient safety issues,” said Jay Redan, M.D., FACS, Medical Director of Minimally Invasive General Surgery at Florida Hospital Celebration Health and the study's lead investigator. “Our findings suggest that including EXPAREL in a multimodal analgesic regimen can reduce the occurrence of opioid-related adverse events, and is associated with statistically significant reductions in urinary retention, respiratory depression and risk of falls after surgery.” The study evaluated 82 patients undergoing open ventral hernia repair or laparoscopic colon resection, all of whom were treated by Dr. Redan. Thirty-seven patients received the SOC: intravenous hydromorphone or morphine with or without epidurals and/or IV acetaminophen. The other 45 patients received infiltration with EXPAREL in addition to the SOC. Key findings include: Patients in the EXPAREL group experienced statistically significant reductions in the incidence of: Urinary retention (0% in the EXPAREL group vs 10.8% in the SOC group; P
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.